Cerebrovascular Risk in Chronic Glomerulonephritis: Clinical and Functional Implications
DOI:
https://doi.org/10.61788/njn.spec.17.05Keywords:
cerebrovascular diseases, risk factors, chronic glomerulonephritis, chronic kidney diseaseAbstract
Studies of recent years found that, in more than half of people with pre-dialysis stages of chronic kidney disease, death occurs as a result of cardiovascular diseases.
Purpose of the study. Study of the prevalence of risk factors for cerebrovascular diseases in chronic glomerulonephritis (CGN) at pre-dialysis stage of the disease.
Materials and methods. 521 patients (351 men and 170 women) with CGN at pre-dialysis stage of the disease were examined. Mean age of the examinees was 37.7±11.7 years.
Results. Compared to the group of men, women showed significantly higher rates of tachycardia (67.6% vs. 28.4%, p<0.005) and stage II arterial hypertension (96.4% vs. 13.3%, p<0.001). In the examined cohort, the share of males with increased linear dimensions of the heart prevailed noticeably. Among female patients, such CVD risk factors as high level of C-reactive protein (41.1% vs. 22.7%, p<0.005), hyperfibrinogenemia (80.5% vs. 69.8%, p<0.005), anemia (40.5% vs 25.6%, p<0.005) were significantly more frequent; and there was a significant decrease in glomerular filtration rate [66 (37-86) ml/min vs. 85 (48-111) ml/min; p=0.000], compared to male patients.
Conclusions. In patients with chronic glomerulonephritis at pre-dialysis stage of the disease, high prevalence of risk factors for cerebrovascular diseases is observed. Leading positions belong to tachycardia, arterial hypertension and excess body weight. In females, anemia, hyperfibrinogenemia and high level of C-reactive protein that are associated with a significant slowing of the glomerular filtration rate are registered significantly more often.
References
Бокерия Л.А. Профилактика инсульта при фибрилляции предсердий. Анналы аритмологии. 2005; 3: 45-54.
Ватутин Н.Т., Смирнова А.С., Гриценко Ю.П. Диагностика, лечение и профилактика подагры: международные клинические рекомендации. Современная ревматология. 2015;9(3):70-72. doi: http://dx.doi.org/10.14412/1996-7012-2015-3-70-72.
Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.328 с.
Житкова Ю.В, Гаспарян А.А, Хасанова Д.Р. и др. Генетические и функциональные факторы в развитии когнитивных нарушений при артериальной гипертензии (проспективное исследование). Неврология, нейропсихиатрия, психосоматика. 2016;8(4):14-20. doi:10.14412/2074-2711-2016-4-14-20.
Здоровье населения и деятельность организаций здравоохранения Кыргызской Республики в 2015 году. Республиканский медико-информационный центр. Бишкек. 2016.
Котова О.В., Акарачкова Е.С. Хроническая ишемия головного мозга: патогенетические механизмы и принципы лечения. Фарматека. 2010;8:57-61.
Кутырина И.М., Швецов М.Ю., Фомин В.В. и др. Клинические рекомендации «Диагностика и лечение артериальной гипертензии при хронической болезни почек». Москва. 2014.1-74.
Люсов В.А, Харченко В.И, Какорин В.А. и др. Определение целевых уровней артериального давления при гипотензивной терапии у больных с тяжелой, резистентной к терапии, артериальной гипертонией. Российский кардиологический журнал. 2008;2(70):67-81.
Мешкова К.С., Гудкова В.В., Стаховская Л.В. Факторы риска и профилактика инсульта. Журнал "Земский Врач". 2013;2(19)16-19.
Моисеев С.В., Киякбаев Г.Г., Фомин В.В. Новые пероральные антикоагулянты в профилактике инсульта у больных с фибрилляцией предсердий и хронической болезнью почек. Клиническая фармакология и терапия. 2015;3:24:5-11.
Мухин Н.А. Нефрология. Национальное руководство. Краткое издание. ГЭОТАР-МЕД. 2016. 608 с.
Орешников Е.В, Орешникова С.Ф. Прогностическое значение показателей обмена мочевой кислоты в острейшем периоде церебрального ишемического инсульта. Неврологический журнал. 2008;6:25-32.
Орлов В.Н. Руководство по электрокардиографии. 7-е издание. Издательство: М.: МИА. 2012. 560 с.
Рогова И.В., Фомин В.В., Дамулин И.В.. и др. Сосудистые когнитивные нарушения при хронической болезни почек. Неврология, нейропсихиатрия, психосоматика. 2015;(1):11-18.
Самохвалова ЕВ, Гераскина ЛА, Фонякин АВ. Ишемический инсульт и вариабельность ритма сердца. Креативная кардиология. 2008;(1):93-101.
Свистунов АА, Головачева ТВ, Скворцов КЮ. И др. Частота сердечных сокращений как фактор риска развития сердечно-сосудистых заболеваний. Артериальная гипертензия. 2008;4:14:324-331.
Скворцова ВИ. Артериальная гипертония и цереброваскулярные нарушения. Системные гипертензии. 2005;2:3-10.
Соловьева ЭЮ, Карнеев АН, Федин АИ. Патогенетическое обоснование антиоксидантной терапии при хронической ишемии мозга. Эффективная фармакотерапия в неврологии и психиатрии. 2009;3:6-12.
Танашян ММ, Лагода ОВ, Антонова КВ, Раскуражев АА. Основные патогенетические механизмы развития сосудистой патологии мозга при атеросклерозе и метаболическом синдроме: поиск путей коррекции. Анналы клинической и экспериментальной неврологии. 2016;2:10:5-10.
Фонякин АВ, Гераскина ЛА. Гиполипидемическая терапия и профилактика инсульта. Практические рекомендации. РМЖ. 2015;28:1660-1664.
Фонякин АВ, Гераскина ЛА. Статины в профилактике и лечении ишемического инсульта. Анналы клинической и экспериментальной неврологии. 2014;1:49-55.
Якупов ЭЗ, Овсянникова КС. Оценка межполушарной асимметрии по данным анализа варибельности ритма сердца у пациентов в остром периоде ишемического инсульта. Журнал «Асимметрия» 2015;9(1).
Amarenco P, Labreuche J, Lavallee P, Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and uptodate metaanalysis. Stroke.2004;35:(12):2902-2909. doi: 10.1161/01.STR.0000147965.52712.fa.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and upto-date metaanalysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-463. doi: 10.1016/S1474-4422(09)70058-4.
Ammirati E, Fogacci F. Clinical relevance of biomarkers for the identification of patients with carotid atherosclerotic plaque: Potential role and limitations of cysteine protease legumain.Atherosclerosis. 2010;257:248-249. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2017.01.003.
Arnold J, Sims D, Ferro CJ. Modulation of stroke risk in chronic kidney disease. Clinical kidney journal. 2016;1:9(1):29-38. doi: https://doi.org/10.1093/ckj/sfv136.
Bainbridge SA, von Versen-Höynck F, Roberts JM. Uric acid inhibits placental system A amino acid uptake. Placenta 2009; 30 (2): 195-200. doi: 10.1016/j.placenta.2008.10.015.
Bang OY. Advances in biomarker for stroke patients: from marker to regulatorPrecision and Future Medicine 2017;1(1):32-42. https://doi.org/10.23838/pfm.2017.00052.
Bassiouny HS, Zarins CK, Kadowaki MH. et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994;19(3):426-434. PMID:8126855.
Black-Maier E, Piccini JP. Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? Heart Published Online First: 09 January 2017. doi: 10.1136/heartjnl-2016-310540.
Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke. 2007; 38: 3127-3132. doi: 10.1161/STROKEAHA.107.489807.
Burkhardt R. Hyperlipidemia and cardiovascular disease: reinforcement for ‘lower is better’. Current opinion in lipidology. 2015 Oct 1;26(5):468-469. doi: 10.1097/MOL.0000000000000221.
Bustamante A, Vilar-Bergua A, Guettier S. et al. C-reactive protein in the detection of post-stroke infections: systematic review and individual participant data analysis. J Neurochem. 2017 Apr;141(2):305-314. doi: 10.1111/jnc.13973.
Cannon C, Braunwald E, McCabe CH. et al. Intensive versus Moderate Lipid-lowering with statins after Acute Coronary Syndromes. N Engl J Med 2004;350:1495-504.
Caplin B, Nitsch D. Urinary biomarkers of tubular injury in chronic kidney disease. Kidney International. 2017; 91(1):21-23. doi: http://dx.doi.org/10.1016/j.kint.2016.10.003.
Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho M.A. Statins in Stroke Prevention: Present and Future. Curr Pharm Des. 2016;22(30):4638-4644. PMID:27160755.
Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;14:37(39):2999-3058. doi: https://doi.org/10.1093/eurheartj/ehw272.
Caterina R, Scarano M, Marfisi R.M. et al. Cholesterol Lowering Interventions and Stroke. J. Am. Coll. Cardiol. 2010;55 (3):198-211. doi: 10.1016/j.jacc.2009.07.062.
Chen Y, Shen F, Liu J, Yang G. Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for stroke. Stroke and Vascular Neurology. e000045. Accessed April 16, 2017. doi: 10.1136/svn-2016-000045.
Cho EY, Myoung C, Park H-s. et al. Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. PLoS ONE. 2017;12(1): e0170017. https://doi.org/10.1371/journal.pone.0170017.
Craggs LJ, Yamamoto Y, Deramecourt V, Kalaria RN. Microvascular pathology and morphometrics of sporadic and hereditary small vessel diseases of the brain. Brain Pathology. 2014;1;24(5):495-509. doi: 10.1111/bpa.12177.
De Weerd, Greving M, Hedblad JP, Lorenz B.et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke. 2010;41:1294-7. doi: 10.1161/STROKEAHA.110.581058.
Denes A, Pinteaux E, Rothwell NJ, Allan SM. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovascular Diseases. 2011;18;32(6):517-527. https://doi.org/10.1159/000332205.
Di Donato I, Bianchi S, De Stefano N. et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC medicine. 2017;24:15(1):41. doi: 10.1186/s12916-017-0778-8.
Diener HC, Katsarava Z, Weimar C. Headache associated with ischemic cerebrovascular disease. Revue neurologique. 2008;31:164(10):819-824. https://doi.org/10.1016/j.neurol.2008.07.008.
Ding L, Hong Y, Peng B. Association between large artery atherosclerosis and cerebral microbleeds: a systematic review and meta-analysis. Stroke and Vascular Neurology. 2017;00:e000049. doi:10.1136/svn-2016-000049.
Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. The Lancet. 2016;26:388(10046):806-817. doi.org/10.1016/S0140-6736(16)31257-0.
Go АS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
Goyal H, Mohanty S, Sharma M. Rani A.Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Indian J Nephrol. 2017;27(1): 44-50. doi: 10.4103/0971-4065.179301.
Grassi D, Ferri L, Desideri G. et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Current pharmaceutical design. 2013;1:19(13):2432-8. PMCID:PMC3606968.
Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet.1998;351:1755-1762.
Hart R, Halperin J. Atrial fibrillation and stroke: concepts and controversies. Stroke.2001;32:803-8. PMID:11239205.
Heine GH, Brandenburg V. Anticoagulation, atrial fibrillation, and chronic kidney disease-whose side are you on? Kidney Int. 2017;91(4):778-780. doi: 10.1016/j.kint.2016.11.028.
Hermus L, Lefrandt JD, Tio RA. et al. Carotid plaque formation and serum biomarkers. Atherosclerosis. 2010;213(1):21-9. doi: 10.1016/j.atherosclerosis.2010.05.013.
Huikuri HV, Jokinen V, Syvanne M. et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19(8):1979-1985. PMID:10446081.
Idicula TT, Brogger J, Naess H. et al. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the ′Bergen stroke study′. BMC Neurol. 2009;9:18. doi: 10.1186/1471-2377-9-18.
Iguchi Y, Kimura K, Kobayashi K. Relation of atrial fibrillation to glomerular filtration rate. Am. J. Cardiol. 2008;102(8):1056-9. doi: 10.1016/j.amjcard.2008.06.018.
Ioachimescu AG, Brennan DM, Hoar BM. et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58(2): 623-630. doi: 10.1002/art.23121.
Iwaki H, Kuriyama M, Neshige S. et al. Acute ischemic stroke associated with nephrotic syndrome: Incidence and significance-Retrospective cohort study. еNeurological Sci. 2015;31:1(3):47-50. doi: http://dx.doi.org/10.1016/j.ensci.2015.10.002.
Kaur I, Khurana A, Kaur JS, Mohan G. Evaluation of serum uric acid in acute ischaemic stroke. Int J Adv Med. 2017;4(1):60-65. doi: http://dx.doi.org/10.18203/2349-3933.ijam20170036.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Supplement. 2013; 3:1-150.
Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). European journal of cardio-thoracic surgery. 2016;23:ezw313. doi:10.1093/ejcts/ezw313.
Kong X, Ma X, Tang L. et al. Arterial stiffness evaluated by carotid‐femoral pulse wave velocity increases the risk of chronic kidney disease in a Chinese population‐based cohort. Nephrology. 2017;1;22(3):205-212. doi:10.1111/nep.12750.
Koton S, Howard SC, Warlow CP. et al. Serum urate predicts long-term risk of acute coronary events in women aft er a transient ischaemic attack and stroke. Cerebrovasc Dis. 2008;26:517-524.
Kovesdy CP, Furth S, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2017;25:22(1):5-11. http://dx.doi.org/10.1080/16089677.2017.1299975.
Kumai Y, Kamouchi M, Hata J. et al. FSR Investigators. Proteinuria and clinical outcomes after ischemic stroke. Neurology. 2012;78:1909-1915. doi: 10.1212/WNL.0b013e318259e110.
Kurth T, Gaziano JM, Berger K.et al. Body mass index and the risk of stroke in men.Arch Intern Med. 2002 Dec 9-23;162(22):2557-2562. PMID:12456227.
Lewis A, Segal A. Hyperlipidemia and primary prevention of stroke: does risk factor identification and reduction really work?. Current atherosclerosis reports. 2010;1:12(4):225-229. doi:10.1007/s11883-010-0117-4.
Liberman AL, Zandieh A, Loomis C. et al. Symptomatic Carotid Occlusion Is Frequently Associated With Microembolization. Stroke. 2017; STROKEAHA.116.015375. doi.org/10.1161/STROKEAHA.116.015375.
Lucchi T., Vergani C. Dislipidemia e statine: dalle linee guida alla pratica clinica. Una rassegna aggiornata della letteratura. G Ital Cardiol 2014;15(3):149-160. doi: 10.1714/1463.16163.
Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke. 2005;1:36(10):2138-2142. https://doi.org/10.1161/01.STR.0000181740.74005.ee.
Mancia G, De Backer G, Dominiczak A. et al. The task force for the management of arterial hypertension of the European Societyof Hypertension, The task force for themanagement of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J.2007;28(12):1462−1536.doi: https://doi.org/10.1093/eurheartj/ehm236.
Mancia G, Fagard R, Narkiewicz K. et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31(7):1281-357.PMID:26252317. doi: 10.1097/MD.0000000000001317.
Mangoni AA, Mircoli L, Giannattasio C. et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996;14(7):897-901. PMID:8818929.
McKiney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43(8):2149-56. doi: 10.1161/STROKEAHA.112.655894.
Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease. Cerebrovasc Dis. 2016;42(3-4):255-262. PMID: 27173592. doi: 10.1159/000446082.
Mostafa MA, Elewa MK, Mohamed NA. Admission leukocytosis, C-reactive protein and erythrocyte sedimentation rate in acute noncardioembolic cerebral ischemia: influence on early outcome. Egypt J Neurol Psychiat Neurosurg. 2015;52(4):223-227. doi: 10.4103/1110-1083.170651.
Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Advances in chronic kidney disease. 2008;30;15(2):123-132. https://doi.org/10.1053/j.ackd.2008.01.010.
Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clinics in Office Practice. 2013;31:40(1):195-211. doi: 10.1016/j.pop.2012.11.003.
Nombela F, Blanko M, Moro MA. et al. Influence of statin withdrawal on acute ischemic stroke. Stroke. 2006;37:686.
O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376(9735):112-123. doi: 10.1016/S0140-6736(10)60834-3.
Oesch L, Tatlisumak T, Arnold M, Sarikaya H. "Obesity paradox in stroke-Myth or reality? A systematic review." PLoS One 12.3.2017; e0171334. doi: 10.1371/journal.pone.0171334.
Olesen JB, Lip GY, Kamper AL. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;16;367(7):625-635. doi: 10.1056/NEJMoa1105594.
Perski A, Olsson G, Landou C. et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J.1992;123:609-616. doi: http://dx.doi.org/10.1016/0002-8703(92)90497-J.
Piccardi B, Giralt D, Bustamante A. Blood markers of inflammation and endothelial dysfunction in cardioembolic stroke: systematic review and meta-analysis. Biomarkers. 2017;22(3-4):200-209. doi: 10.1080/1354750X.2017.1286689.
Power A. Stroke in dialysis and chronic kidney disease. Blood purification. 2013;20;36 (3-4):179-183. https://doi.org/10.1159/000356086.
Reeves MJ, Gargano JW, Luo Z. et al. Effect of pretreatment with statins on ischemic stroke outcomes.Stroke.2008;39 (6):1779-1785. doi: 10.1161/STROKEAHA.107.501700.
Reuter B, Rodemer C, Grudzenski S. et al. Gene expression analysis of matrix metalloproteinases their ingibitors in an invitro.Abstracts of European Stroke conference. Hamburg, Germany. 2011; 362.
Rodgers A, Mac Mahon S, Gamble G. et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ.1996;313:147.
Schaller B. Extracranial-intracranial bypass to reduce the risk of ischemic stroke in intracranial aneurysms of the anterior cerebral circulation: a systematic review. J Stroke Cerebrovasc Dis. 2008;17:287-298. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.010.
Shigematsu K, Watanabe Y, Nakano H. Influences of hyperlipidemia history on stroke outcome; a retrospective cohort study based on the Kyoto Stroke Registry. BMC neurology. 2015;25:15(1):44. doi: 10.1186/s12883-015-0297-1.
Spiga R, Marini MA, Mancuso E. et al. Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-κB Signaling Pathway in Hep G2 Cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;ATVBAHA.117.309128. https://doi.org/10.1161/ATVBAHA.117.309128.
Stamler J. Epidemic obesity in the United States. Arch Intern Med. 1993;153(9): 1040-4. PMID:8481071.
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321(3): 129-135. doi: 10.1056/NEJM198907203210301.
Stewart S, Hart C, Hole D. et al. A population 4 based study of the long 4 term risks associated with atrial fibrillation: 204year follow4up of the Renfrew/Paisley study. Am. J. Med. 2002;113:359-364. PMID:12401529.
Su X, Zhang L, Lv J. et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. American Journal of Kidney Diseases. 2016;30:67(6):881-892. https://doi.org/10.1053/j.ajkd.2016.01.016.
Tavil Y, Kaya MG, Oktar SO. et al. Uric acid level and its association with carotid intimamedia thickness in patients with hypertension.Atherosclerosis. 2008;197(1):159-163. doi: 10.1016/j.atherosclerosis.2007.03.008.
Toyoda K. Cerebral Small Vessel Disease and Chronic Kidney. Journal of stroke. 2015;17(1):31-37. http://dx.doi.org/10.5853/jos.2015.17.1.31.
Tsagalis G, Bakirtzi N, Manios E. et al. Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece. Artif Organs. 2011;35:916-922.
Valente MA, Hillege HL, Navis G. et al. The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. European journal of heart failure. 2014;1:16(1):86-94. doi:10.1093/eurjhf/hft128.
Xiang DM, Song XZ, Zhou ZM. et al. Chronic kidney disease promotes chronic inflammation in visceral white adipose tissue. Am J Physiol Renal Physiol. 2017;312(4):F689-F701. doi: 10.1152/ajprenal.00584.
Xu T, Ke K. C-reactive protein and ischemic stroke risk in general population: A dose-response meta-analysis of prospective studies. Int J Cardiol. 2015;190:264-7. doi: 10.1016/j.ijcard.2015.04.176.
Yahalom G, Schwartz R, Schwammenthal Y. et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke. 2009;40:1296-303. doi: 10.1161/STROKEAHA.108.520882.
Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. doi: 10.1016/S0140-6736(04)17018-9.
Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. Canadian Medical Association Journal. 2015;23:cmaj-150535. doi:10.1503/cmaj.150535.
Zhang D, Wang G, Fang J, Mercado C. Hyperlipidemia and medical expenditures by cardiovascular disease status in US adults. Medical Care. 2017;1:55(1):4-11. doi: 10.1097/MLR.0000000000000663.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
